Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.44
-0.33 (-3.76%)
Mar 5, 2026, 4:00 PM EST - Market closed
Emergent BioSolutions Employees
Emergent BioSolutions had 900 employees as of December 31, 2024. The number of employees decreased by 700 or -43.75% compared to the previous year.
Employees
900
Change (1Y)
-700
Growth (1Y)
-43.75%
Revenue / Employee
$825,444
Profits / Employee
$58,444
Market Cap
436.95M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Canopy Growth | 960 |
| Organogenesis Holdings | 854 |
| Kamada | 420 |
| Evolus | 329 |
| Esperion Therapeutics | 304 |
| Ironwood Pharmaceuticals | 253 |
| Akebia Therapeutics | 194 |
| Aquestive Therapeutics | 142 |
EBS News
- 2 days ago - Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors - GlobeNewsWire
- 5 days ago - Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture - Seeking Alpha
- 7 days ago - Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 7 days ago - Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 days ago - Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness - GlobeNewsWire
- 7 days ago - Emergent BioSolutions Announces New $50 Million Stock Repurchase Program - GlobeNewsWire
- 21 days ago - Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks - GlobeNewsWire
- 21 days ago - Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire